Table of Contents
ISRN Medicinal Chemistry
Volume 2013 (2013), Article ID 891089, 6 pages
http://dx.doi.org/10.1155/2013/891089
Review Article

A Critical Prospect of Structural Designing of Avian Influenza A/H5N1 Neuraminidase Inhibitors That Evade Tamiflu Resistance

1Department of Material Science and Chemistry, Faculty of Systems Engineering, Wakayama University, 930 Sakaedani, Wakayama 640-8510, Japan
2Department of Natural Sciences, Belgrade Institute of Science and Technology, 11060 Belgrade, Serbia

Received 26 June 2013; Accepted 4 September 2013

Academic Editors: J. Bustamante, M. A. De Souza, K. Sawanyawisuth, and F. Uribe-Salas

Copyright © 2013 Petar M. Mitrasinovic. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Mitrasinovic, “Prefacein,” in Global View of the Fight Against Influenza, P. M. Mitrasinovic, Ed., pp. 13–17, Nova Science, New York, NY, USA, 2009. View at Google Scholar
  2. P. M. Mitrasinovic, “Recent developments and prospects for influenza M2 ion channel inhibitors that circumvent amantadine resistance,” Current Bioinformatics, vol. 7, no. 4, pp. 466–473, 2012. View at Google Scholar
  3. P. M. Mitrasinovic, “Advances in the structure-based design of the influenza a neuraminidase inhibitors,” Current Drug Targets, vol. 11, no. 3, pp. 315–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Laver, “Flu drugs: pathway to discovery,” in Global View of the Fight Against Influenza, P. M. Mitrasinovic, Ed., pp. 21–28, Nova Science, New York, NY, USA, 2009. View at Google Scholar
  5. R. J. Russell, L. F. Haire, D. J. Stevens et al., “The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design,” Nature, vol. 443, no. 7107, pp. 45–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. S. Kerry and R. J. Russell, “The impact of structural biology on the understanding of the influenza virus and the rational design of antivirals,” in Global View of the Fight Against Influenza, P. M. Mitrasinovic, Ed., pp. 155–184, Nova Science Publishers, New York, NY, USA, 2009. View at Google Scholar
  7. M. L. Mihajlovic and P. M. Mitrasinovic, “Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV),” Biophysical Chemistry, vol. 136, no. 2-3, pp. 152–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. L. Mihajlovic and P. M. Mitrasinovic, “Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs),” Molecular Simulation, vol. 35, no. 4, pp. 311–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. M. Mitrasinovic, “On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA),” Biophysical Chemistry, vol. 140, no. 1–3, pp. 35–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Rungrotmongkol, M. Malaisree, T. Udommaneethanakit, and S. Hannongbua, “Comment on ‘Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)’,” Biophysical Chemistry, vol. 141, no. 1, pp. 131–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. J. Collins, L. F. Haire, Y. P. Lin et al., “Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants,” Nature, vol. 453, no. 7199, pp. 1258–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. Mitrasinovic, “Reply to Comment on ‘Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)’,” Biophysical Chemistry, vol. 141, no. 1, p. 133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Mitrasinovic, “Comment on ‘Comment on ‘another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)’,” Biophysical Chemistry, vol. 154, no. 2-3, p. 102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. E. Amaro, D. D. L. Minh, L. S. Cheng et al., “Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design,” Journal of the American Chemical Society, vol. 129, no. 25, pp. 7764–7765, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Q. Wang, X. C. Cheng, W. L. Dong, R. Wang, and K. Chou, “Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus,” Biochemical and Biophysical Research Communications, vol. 401, no. 2, pp. 188–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. E. Amaro, R. V. Swift, L. Votapka, W. W. Li, R. C. Walker, and R. M. Bush, “Mechanism of 150-cavity formation in influenza neuraminidase,” Nature Communications, vol. 2, no. 1, p. 388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Li, J. Qi, W. Zhang et al., “The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site,” Nature Structural and Molecular Biology, vol. 17, no. 10, pp. 1266–1268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Amaro and W. W. Li, “Emerging methods for ensemble-based virtual screening,” Current Topics in Medicinal Chemistry, vol. 10, no. 1, pp. 3–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. L. S. Cheng, R. E. Amaro, D. Xu, W. W. Li, P. W. Arzberger, and J. A. McCammon, “Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase,” Journal of Medicinal Chemistry, vol. 51, no. 13, pp. 3878–3894, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. N. Varghese, J. L. McKimm-Breschkin, J. B. Caldwell, A. A. Kortt, and P. M. Colman, “The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor,” Proteins, vol. 14, no. 3, pp. 327–332, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. C. L. White, M. N. Janakiraman, W. G. Laver et al., “A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies,” Journal of Molecular Biology, vol. 245, no. 5, pp. 623–634, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. M. von Itzstein, W.-Y. Wu, G. B. Kok et al., “Rational design of potent sialidase-based inhibitors of influenza virus replication,” Nature, vol. 363, no. 6428, pp. 418–423, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. C. U. Kim, W. Lew, M. A. Williams et al., “Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity,” Journal of the American Chemical Society, vol. 119, no. 4, pp. 681–690, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. M. von Itzstein, “The war against influenza: discovery and development of sialidase inhibitors,” Nature Reviews Drug Discovery, vol. 6, no. 12, pp. 967–974, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. Q. M. Le, M. Kiso, K. Someya et al., “Avian flu: isolation of drug-resistant H5N1 virus,” Nature, vol. 437, no. 7062, p. 1108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Moscona, “Global transmission of oseltamivir-resistant influenza,” New England Journal of Medicine, vol. 360, no. 10, pp. 953–956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Moscona, “Medical management of influenza infection,” Annual Review of Medicine, vol. 59, pp. 397–413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. V. P. Mishin, F. G. Hayden, and L. V. Gubareva, “Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4515–4520, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. H. L. Yen, L. M. Herlocher, E. Hoffmann et al., “Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 10, pp. 4075–4084, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. H. Wen, S. Y. Wang, K. Tsai et al., “Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses,” Bioorganic and Medicinal Chemistry, vol. 18, no. 11, pp. 4074–4084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. T. García-Sosa, S. Siid, and U. Maran, “Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant,” Journal of Chemical Information and Modeling, vol. 48, no. 10, pp. 2074–2080, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Li, B. Zhou, and R. Wang, “Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1,” Journal of Molecular Graphics and Modelling, vol. 28, no. 3, pp. 203–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Q. S. Du, S. Q. Wang, and K. C. Chou, “Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus,” Biochemical and Biophysical Research Communications, vol. 362, no. 2, pp. 525–531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Rudrawar, J. C. Dyason, M. Rameix-Welti et al., “Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase,” Nature Communications, vol. 1, no. 8, p. 113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. N. A. Roberts and E. A. Govorkova, “The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses,” in Global View of the Fight Against Influenza, P. M. Mitrasinovic, Ed., pp. 93–118, Nova Science, New York, NY, USA, 2009. View at Google Scholar
  36. E. A. Govorkova, I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster, “Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 10, pp. 2723–2732, 2001. View at Publisher · View at Google Scholar · View at Scopus